The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The US FDA re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication ...
Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.